NLRP3 and early-onset autosomal dominant Alzheimer disease: In addition, the involvement of NF-κB-NLRP3 inflammasome pathway inhibition by NTN-1 might lead to a new agent for the underlying pathophysiology that is responsible for antagonizing and alleviating Alzheimer's disease.